Monday, 12 Jun 2017
12th ADMET Conference and Exhibition


The SMi Group is proud to announce the return of the 12th annual ADMET conference taking place in London on the 12th – 13th June 2017.

Join our expert speaker panel at the 12th annual ADMET conference for yet another successful run! Presenting new developments, case studies and challenges in the areas of DMPK. PBPK, PKPD, in vivo/ in vitro/ in silico, transporters, hazards and safety assessment, ADMET modelling and many more!

This event will explore ADMET technologies which determine properties of a drug candidate in the preclinical stage of drug discovery, structure based prediction of ADME properties, PK/PD modelling to validate drug targets and toxicity and many more.

ADMET 2017 will provide a series of practical case studies delivered by leading industry experts that will provide executives with useful tools and best practices to:

• Predict drug design interaction
• Evaluate drug design interaction
• Use a population pharmacokinetic approach to assess DDI
• Review the structure based prediction of ADME properties
• Learn about In-Vivo drug-drug interaction
• Optimise human ADMET studies to assess clinically-relevant drug bioavailability
• Gain insight into PK/PD modelling to validate drug targets and toxicity

• Ajit Narang, Senior Scientist, Genentech
• Andreas Reichel, VP, Head Research Pharmacokinetics, Bayer
• Ben-Fillippo Krippendorff, Franchise Leader PK/PD Immunology & Inflammation, Roche
• Carl Petersson, Associate Director Drug Disposition, Merck KGaA
• Eric Blomme, Vice President Preclinical Safety, AbbVie
• Handan He, Director, Section Head, Nonclinical PK/PD, Novartis
• Jackie Bloomer, Director, IVIVT, PTS, GSK
• Kiyoyuki Omoto, Scientist, Associate Research Fellow, Pfizer
• Kunal Taskar, Senior Investigator & Associate Fellow, GSK
• Laurent Salphati, Principal Scientist, Genentech
• Matthias Wittwer, Laboratory Head DMPK-BANP-NCPK, Bayer
• Na Li, Senior Staff Scientist, Corning
• Peter Littlewood, Senior Director Head of DMPK Europe, Vertex Pharmaceuticals
• Rob Young, Senior Scientific Investigator & GSK Associate Fellow, GSK
• Sheila Annie Peters, Head, Translational Quantitative Pharmacology, Merck KGaA
• Timothy Schulz-Utermoehl, Director of DMPK, Sygnature Discovery
• Valeriu Damian, Director System Modeling & Translational Biology, GSK
• Elisabetta Chiarparin, Head of Oncology Analytical and Structural Chemistry, AstraZeneca
• Robert van Waterschoot, Head of Pharmacokinetics, Dynamics & Metabolism (PDM) Leaders, Roche

Genentech, Bayer, Roche, Merck KGaA, AstraZeneca, AbbVie, Novartis, Pfizer, GSK, Corning, Vertex Pharmaceuticals,

• Learn about new technologies for ADMET testing, including computer based testing
• ADME/PK Optimisation for Drug Design and Discovery
• Preclinical In Vivo Pharmacology Testing and Translational PK/PD
• Developments in Drug Screening Technology
• In Vitro to Human In Vivo Translation
• Physiologically Based PK Modeling
• Predictive Human Toxicity, Transporters and ADMET Studies from Vertex, Merck KGaA, GSK
• Listen to presentations explaining methods to predicting Drug-Drug Interactions with in vivo and in vitro data knowledge
Book by 28th February - save £300
Book by 3th1 March - save £200
Book by 28th April - save £100

ADMET, in vivo, in vitro, in silico, Pharmacology, DDI, Genotoxic, Assay, DMPK, Metabolites

Venue: Copthorne Tara Hotel
Location: Kensington, London
Country: United Kingdom

Organiser Contact Details:
Kyra Williams

T: 02078276012

Delegates Registration

12th ADMET Conference and Exhibition
Copthorne Tara Hotel
Kensington, London

Hosted By
The SMi Group
SMi Group is at the forefront of linking businesses with information, organising over 160 Conferences and 100 Executive Briefings every year.
Web Site Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'eventflo'
type the following in your web browser: